Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update

Wedbush Assumes Ultragenyx Pharma (RARE) at Outperform

February 17, 2017 12:09 PM EST

Wedbush assumed coverage on Ultragenyx Pharma (NASDAQ: RARE) with an Outperform rating and a price target of $88.00.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $76.82 yesterday.

... More

Jefferies Reiterates Buy Rating and $109 PT on Ultragenyx (RARE) Following 'Uneventful' 4Q16 Results

February 17, 2017 8:13 AM EST

Jefferies analyst Gena Wang reiterates Buy rating and $109 price target on Ultragenyx Pharmaceuticals (NASDAQ: RARE), noting clinical progress across multiple initiatives, despite an "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.

Wang comments, "RARE 4Q16 EC was largely... More

Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c

February 16, 2017 4:13 PM EST

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

... More